ZYZhuyifan Ye

Zhuyifan Ye

*This is an algorithmically generated author record based on publicly available information.

Zhuyifan Ye has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • TradePool: A Novel Interpretable Framework for Quantifying Atomic Attribution Values in Molecular Property Prediction

    by Bingwei Ni, Wanxiang Shen, Zhuyifan Ye

    The interpretability of GNNs (Graph Neural Network Models) has always been a focal point in the field of compound property prediction. GNNs perform well in modeling small-sample compound data sets, but current interpretable methods struggle to accurately interpret atomic attribution values, quantitative measures of individual atom attribution to model predictions. This makes the optimization of lead compounds reliant on the experience of senior chemists, slowing the drug development process. The rapid expansion of the AI-generated chemical space necessitates efficient interpretation of AI (XAI) methods. These tools can uncover insights beyond human intuition, complementing expert knowledge and significantly accelerating optimization cycles. To tackle these challenges, we propose a novel two-stage atomic attribution value calculation framework for GNNs, which includes model training based on structural pooling and atomic attribution value calculation based on substructure mapping. Our interpretable framework quantifies task-specific atomic attribution values─enhancing atomic attribution accuracy (agreement between computed and ground-truth atomic attribution values) by 30%/20%/15% with 0.93/0.63/0.88 Pearson correlation coefficient (Pearson's r) for GCNs on aromaticity/LogP/TPSA data sets, surpassing commonly used interpretable methods that achieve only 0-0.3 Pearson's r. Additionally, our method is not sensitive to changes in model parameters and provides relatively stable prediction results for changes in the compound structures.


  • An Integrated AI‐PBPK Platform for Predicting Drug In Vivo Fate and Tissue Distribution in Human and Inter‐Species Extrapolation

    by Wei Wang, Nannan Wang, Yiyang Wu, Zhuyifan Ye, Liang Zhao, Xianfeng Chen, Defang Ouyang

    Optimal pharmacokinetic (PK) profile, including tissue distribution, is pivotal for a drug achieving success in clinical trials. Traditionally, PK estimation in early drug development has relied on extensive in vitro and in vivo testing to assess drug‐like properties, a process that is not only costly and time‐consuming but also limited in its ability to evaluate the synergistic effects of multiple properties. This study aims to develop an integrated artificial intelligence (AI) and physiologically based pharmacokinetic (PBPK) platform to rapidly estimate drug in vivo fate based solely on molecular structures. The AI models were trained to predict eight types of key properties (solubility, pKa values, crystal density, intrinsic dissolution rate, apparent permeability, protein unbound fraction, plasma clearance, and tissue partition coefficients for 15 organs), from which the PBPK model forecasted PK curves without further training. The AI‐PBPK approach was validated against human PK data of 71 intravenous and 606 oral administrations collected from the PK‐DB database. The results were robust, with most of the AUC predictions falling within two and threefold error ranges. The AI‐PBPK model also accurately predicted drug organ selectivity, and for drugs exhibiting high plasma clearance, predictions were optimized through an inter‐species extrapolation approach. This study illustrates that the developed modeling strategy adeptly addresses pivotal PK challenges in drug discovery and aligns with contemporary drug development processes. The modeling system can guide candidate selection, advancing more drugs with favorable PK profiles into clinical trials, thereby significantly enhancing the efficiency of drug development.


  • Open Access

    FormulationBCS: A Machine Learning Platform Based on Diverse Molecular Representations for Biopharmaceutical Classification System (BCS) Class Prediction

    by Zheng Wu, Nannan Wang, Zhuyifan Ye, Huanle Xu, Ging Chan, Defang Ouyang

    The Biopharmaceutics Classification System (BCS) has facilitated biowaivers and played a significant role in enhancing drug regulation and development efficiency. However, the productivity of measuring the key discriminative properties of BCS, solubility and permeability, still requires improvement, limiting high-throughput applications of BCS, which is essential for evaluating drug candidate developability and guiding formulation decisions in the early stages of drug development. In recent years, advancements in machine learning (ML) and molecular characterization have revealed the potential of quantitative structure-performance relationships (QSPR) for rapid and accurate in silico BCS classification. The present study aims to develop a web platform for high-throughput BCS classification based on high-performance ML models. Initially, four data sets of BCS-related molecular properties: log S, log P, log D, and log Papp were curated. Subsequently, 6 ML algorithms or deep learning frameworks were employed to construct models, with diverse molecular representations ranging from one-dimensional molecular fingerprints, descriptors, and molecular graphs to three-dimensional molecular spatial coordinates. By comparing different combinations of molecular representations and learning algorithms, LightGBM exhibited excellent performance in solubility prediction, with an R2 of 0.84; AttentiveFP outperformed others in permeability prediction, with R2 values of 0.96 and 0.76 for log P and log D, respectively; and XGBoost was the most accurate for log Papp prediction, with an R2 of 0.71. When externally validated on a marketed drug BCS category data set, the best-performing models achieved classification accuracies of over 77 and 73% for solubility and permeability, respectively. Finally, the well-trained models were embedded into the first ML-based BCS class prediction web platform (x f), enabling pharmaceutical scientists to quickly determine the BCS category of candidate drugs, which will aid in the high-throughput BCS assessment for candidate drugs during the preformulation stage, thereby promoting reduced risk and enhanced efficiency in drug development and regulation.


  • Open Access

    Interpretable machine learning methods for in vitro pharmaceutical formulation development

    by Zhuyifan Ye, Wenmian Yang, Yilong Yang, Defang Ouyang

    Background: Machine learning has become an alternative approach for pharmaceutical formulation development. However, many machine learning applications in pharmaceutics only focus on model performance rather than model interpretability.Aim: This study aims to propose an attention‐based deep neural network (DNN) for pharmaceutical formulation development.Methods: An attention‐based DNN, AttPharm, was proposed. AttPharm separately handled feature values and feature physical meaning by representation learning to successfully apply the attention mechanism to the pharmaceutical tabular data. Furthermore, the distributions of the attention weights were computed using AttPharm. Two post hoc methods, local interpretable model‐agnostic explanation (LIME) and TreeSHAP, were utilized to obtain the post hoc model interpretability for lightGBM.Results: The results demonstrated that AttPharm significantly improved the model performance of plain neural networks on a pharmaceutical cyclodextrin dataset because the attention mechanism could extract related features and find minute variation. Notably, the attention weights were analyzed, which illustrated global and local feature‐level and sample‐level model interpretability, thus providing insights for formulation design. Comparing with post hoc methods, AttPharm can be used without the concern of the faithfulness of interpretability.Conclusion: This is the first step in applying the attention‐based DNN to pharmaceutical formulation development. Considering the importance of model interpretability, the proposed approach may have a wide range of applications in pharmaceutics.